Covalon Technologies Ltd. (COV.V)
CAD 2.3
(-4.17%)
CAD 2.3
(-4.17%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.18 CAD | 52.63% |
| 2022 | -0.38 CAD | -560.05% |
| 2021 | 0.08 CAD | 130.59% |
| 2020 | -0.27 CAD | 34.15% |
| 2019 | -0.41 CAD | -685.71% |
| 2018 | 0.07 CAD | -22.22% |
| 2017 | 0.09 CAD | 134.62% |
| 2016 | -0.26 CAD | -160.0% |
| 2015 | -0.10 CAD | -138.46% |
| 2014 | 0.26 CAD | 336.36% |
| 2013 | -0.11 CAD | 77.08% |
| 2012 | -0.48 CAD | -11.63% |
| 2011 | -0.43 CAD | 18.87% |
| 2010 | -0.53 CAD | 19.7% |
| 2009 | -0.66 CAD | -29.41% |
| 2008 | -0.51 CAD | 1.92% |
| 2007 | -0.52 CAD | -15.56% |
| 2006 | -0.45 CAD | 4.26% |
| 2005 | -0.47 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.03 CAD | 71.25% |
| 2024 Q2 | 0.06 CAD | 271.59% |
| 2024 Q3 | 0.06 CAD | -0.84% |
| 2023 Q1 | -0.02 CAD | 90.56% |
| 2023 Q4 | -0.12 CAD | -497.01% |
| 2023 Q2 | -0.03 CAD | -85.43% |
| 2023 FY | - CAD | 52.63% |
| 2023 Q3 | -0.02 CAD | 28.21% |
| 2022 Q4 | -0.16 CAD | -148.45% |
| 2022 Q3 | -0.06 CAD | 32.21% |
| 2022 FY | - CAD | -560.05% |
| 2022 Q1 | -0.06 CAD | -106.81% |
| 2022 Q2 | -0.10 CAD | -62.12% |
| 2021 Q4 | 0.86 CAD | 2050.0% |
| 2021 Q1 | -0.01 CAD | 0.0% |
| 2021 FY | - CAD | 130.59% |
| 2021 Q2 | 0.02 CAD | 213.19% |
| 2021 Q3 | 0.04 CAD | 145.4% |
| 2020 Q4 | - CAD | -100.0% |
| 2020 Q3 | 0.01 CAD | 106.67% |
| 2020 FY | - CAD | 34.15% |
| 2020 Q2 | -0.15 CAD | -229.67% |
| 2020 Q1 | -0.05 CAD | 0.0% |
| 2019 Q2 | -0.01 CAD | 87.79% |
| 2019 FY | - CAD | -685.71% |
| 2019 Q1 | -0.09 CAD | 0.0% |
| 2019 Q3 | -0.16 CAD | -1423.81% |
| 2019 Q4 | - CAD | 100.0% |
| 2018 Q2 | -0.02 CAD | -200.0% |
| 2018 Q3 | 0.10 CAD | 600.0% |
| 2018 FY | - CAD | -22.22% |
| 2018 Q1 | 0.02 CAD | 0.0% |
| 2018 Q4 | - CAD | -100.0% |
| 2017 Q4 | - CAD | -100.0% |
| 2017 FY | - CAD | 134.62% |
| 2017 Q1 | 0.03 CAD | 0.0% |
| 2017 Q2 | 0.02 CAD | -33.33% |
| 2017 Q3 | 0.03 CAD | 50.0% |
| 2016 Q1 | 0.03 CAD | 0.0% |
| 2016 Q4 | - CAD | 100.0% |
| 2016 Q3 | -0.01 CAD | 89.1% |
| 2016 Q2 | -0.10 CAD | -433.33% |
| 2016 FY | - CAD | -160.0% |
| 2015 FY | - CAD | -138.46% |
| 2015 Q3 | -0.01 CAD | -146.33% |
| 2015 Q4 | - CAD | 100.0% |
| 2015 Q2 | 0.03 CAD | 250.0% |
| 2015 Q1 | -0.02 CAD | 0.0% |
| 2014 Q3 | -0.03 CAD | -160.0% |
| 2014 Q4 | - CAD | 100.0% |
| 2014 FY | - CAD | 336.36% |
| 2014 Q1 | 0.34 CAD | 0.0% |
| 2014 Q2 | 0.05 CAD | -85.29% |
| 2013 Q2 | -0.06 CAD | 36.5% |
| 2013 Q3 | 0.03 CAD | 149.83% |
| 2013 FY | - CAD | 77.08% |
| 2013 Q4 | - CAD | -100.0% |
| 2013 Q1 | -0.09 CAD | 0.0% |
| 2012 Q3 | -0.10 CAD | 0.0% |
| 2012 Q4 | - CAD | 100.0% |
| 2012 FY | - CAD | -11.63% |
| 2012 Q1 | -0.10 CAD | 0.0% |
| 2012 Q2 | -0.10 CAD | -4.06% |
| 2011 Q2 | -0.06 CAD | 31.55% |
| 2011 Q1 | -0.08 CAD | 0.0% |
| 2011 FY | - CAD | 18.87% |
| 2011 Q4 | - CAD | 100.0% |
| 2011 Q3 | -0.16 CAD | -178.26% |
| 2010 Q1 | -0.06 CAD | 0.0% |
| 2010 Q4 | - CAD | 100.0% |
| 2010 Q3 | -0.09 CAD | 67.86% |
| 2010 Q2 | -0.28 CAD | -369.8% |
| 2010 FY | - CAD | 19.7% |
| 2009 FY | - CAD | -29.41% |
| 2009 Q1 | -0.18 CAD | 0.0% |
| 2009 Q3 | -0.16 CAD | 11.11% |
| 2009 Q2 | -0.18 CAD | 0.0% |
| 2009 Q4 | - CAD | 100.0% |
| 2008 Q1 | -0.09 CAD | 0.0% |
| 2008 FY | - CAD | 1.92% |
| 2008 Q3 | -0.06 CAD | 53.0% |
| 2008 Q2 | -0.13 CAD | -39.94% |
| 2008 Q4 | - CAD | 100.0% |
| 2007 Q1 | -0.07 CAD | 0.0% |
| 2007 Q3 | -0.13 CAD | -44.77% |
| 2007 Q4 | - CAD | 100.0% |
| 2007 Q2 | -0.09 CAD | -26.3% |
| 2007 FY | - CAD | -15.56% |
| 2006 Q3 | -0.09 CAD | 22.83% |
| 2006 FY | - CAD | 4.26% |
| 2006 Q4 | - CAD | 100.0% |
| 2006 Q1 | -0.11 CAD | 0.0% |
| 2006 Q2 | -0.12 CAD | -9.09% |
| 2005 Q4 | - CAD | 100.0% |
| 2005 Q2 | -0.09 CAD | -93.35% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q1 | -0.05 CAD | 0.0% |
| 2005 Q3 | -0.08 CAD | 13.87% |
| Name | Eps | Eps Difference |
|---|---|---|
| Arch Biopartners Inc. | -0.05 CAD | -237.711% |
| Hemostemix Inc. | -0.03 CAD | -494.059% |
| Universal Ibogaine Inc. | -0.06 CAD | -218.584% |
| Kane Biotech Inc. | -0.04 CAD | -401.393% |
| MedMira Inc. | -0.00 CAD | -4636.842% |
| Marvel Biosciences Corp. | -0.06 CAD | -211.419% |
| NervGen Pharma Corp. | -0.38 CAD | 52.632% |
| XORTX Therapeutics Inc. | -1.44 CAD | 87.5% |